BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 32815153)

  • 21. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
    Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
    Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
    Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
    Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
    Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
    Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telomerase reverse transcriptase (TERT) promoter mutation correlated with intratumoral heterogeneity in hepatocellular carcinoma.
    Kwa WT; Effendi K; Yamazaki K; Kubota N; Hatano M; Ueno A; Masugi Y; Sakamoto M
    Pathol Int; 2020 Sep; 70(9):624-632. PubMed ID: 32559017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonlinear tumor evolution from dysplastic nodules to hepatocellular carcinoma.
    Joung JG; Ha SY; Bae JS; Nam JY; Gwak GY; Lee HO; Son DS; Park CK; Park WY
    Oncotarget; 2017 Jan; 8(2):2076-2082. PubMed ID: 27409339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis.
    Miao R; Luo H; Zhou H; Li G; Bu D; Yang X; Zhao X; Zhang H; Liu S; Zhong Y; Zou Z; Zhao Y; Yu K; He L; Sang X; Zhong S; Huang J; Wu Y; Miksad RA; Robson SC; Jiang C; Zhao Y; Zhao H
    J Hepatol; 2014 Oct; 61(4):840-9. PubMed ID: 24859455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors.
    Furuta M; Ueno M; Fujimoto A; Hayami S; Yasukawa S; Kojima F; Arihiro K; Kawakami Y; Wardell CP; Shiraishi Y; Tanaka H; Nakano K; Maejima K; Sasaki-Oku A; Tokunaga N; Boroevich KA; Abe T; Aikata H; Ohdan H; Gotoh K; Kubo M; Tsunoda T; Miyano S; Chayama K; Yamaue H; Nakagawa H
    J Hepatol; 2017 Feb; 66(2):363-373. PubMed ID: 27742377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis.
    Midorikawa Y; Yamamoto S; Tsuji S; Kamimura N; Ishikawa S; Igarashi H; Makuuchi M; Kokudo N; Sugimura H; Aburatani H
    Hepatology; 2009 Feb; 49(2):513-22. PubMed ID: 19105209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of Genomic, Epigenomic, and Transcriptomic Aberrations during Stepwise Hepatocarcinogenesis.
    Jee BA; Choi JH; Rhee H; Yoon S; Kwon SM; Nahm JH; Yoo JE; Jeon Y; Choi GH; Woo HG; Park YN
    Cancer Res; 2019 Nov; 79(21):5500-5512. PubMed ID: 31506333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.
    Li W; Wu H; Xu X; Zhang Y
    Aging (Albany NY); 2021 Apr; 13(8):11564-11594. PubMed ID: 33867349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer.
    Hlady RA; Zhou D; Puszyk W; Roberts LR; Liu C; Robertson KD
    Epigenetics; 2017 Mar; 12(3):215-225. PubMed ID: 28059585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrative analysis reveals novel driver genes and molecular subclasses of hepatocellular carcinoma.
    Yang L; Zhang Z; Sun Y; Pang S; Yao Q; Lin P; Cheng J; Li J; Ding G; Hui L; Li Y; Li H
    Aging (Albany NY); 2020 Nov; 12(23):23849-23871. PubMed ID: 33221766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma.
    Zhang B; Zhang Y; Zou X; Chan AW; Zhang R; Lee TK; Liu H; Lau EY; Ho NP; Lai PB; Cheung YS; To KF; Wong HK; Choy KW; Keng VW; Chow LM; Chan KK; Cheng AS; Ko BC
    J Pathol; 2017 Dec; 243(4):418-430. PubMed ID: 28862757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features.
    Li X; Xu W; Kang W; Wong SH; Wang M; Zhou Y; Fang X; Zhang X; Yang H; Wong CH; To KF; Chan SL; Chan MTV; Sung JJY; Wu WKK; Yu J
    Theranostics; 2018; 8(6):1740-1751. PubMed ID: 29556353
    [No Abstract]   [Full Text] [Related]  

  • 36. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
    Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
    J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression.
    Oda T; Tsuda H; Sakamoto M; Hirohashi S
    Cancer Lett; 1994 Aug; 83(1-2):197-200. PubMed ID: 8062215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma.
    Lee SE; Chang SH; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
    Oncotarget; 2016 Oct; 7(43):69267-69275. PubMed ID: 27661004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deep whole-genome analysis of 494 hepatocellular carcinomas.
    Chen L; Zhang C; Xue R; Liu M; Bai J; Bao J; Wang Y; Jiang N; Li Z; Wang W; Wang R; Zheng B; Yang A; Hu J; Liu K; Shen S; Zhang Y; Bai M; Wang Y; Zhu Y; Yang S; Gao Q; Gu J; Gao D; Wang XW; Nakagawa H; Zhang N; Wu L; Rozen SG; Bai F; Wang H
    Nature; 2024 Mar; 627(8004):586-593. PubMed ID: 38355797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of genes involved in the regulation of TERT in hepatocellular carcinoma.
    Amisaki M; Tsuchiya H; Sakabe T; Fujiwara Y; Shiota G
    Cancer Sci; 2019 Feb; 110(2):550-560. PubMed ID: 30447097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.